DR. PAUL HUNTER PLOTZ, M.D.
Osteopathic Medicine in Bethesda, MD
License number
Maryland D0013979
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
2
9000 Rockville Pike Bldg 50 ROOM 1503, Bethesda, MD 20892
3221 Livingston St NW, Washington, DC 20015
3221 Livingston St NW, Washington, DC 20015
Phone
(301) 496-9904
(202) 363-0693
(202) 363-0693
Personal information
See more information about PAUL HUNTER PLOTZ at radaris.comName
Address
Phone
3221 Livingston St NW, Washington, DC 20015
Washington, DC
3221 Livingston St NW, Washington, DC 20015
Professional information
Dr. Paul H Plotz, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
9000 Rockville Pike SUITE 50, Bethesda 20892
(301) 496-1474 (Phone), (301) 402-0012 (Fax)
SOUTH DRIVE, MSC 0812
50 Dr South SUITE 50, Bethesda 20892
(301) 594-5283 (Phone)
(301) 496-1474 (Phone), (301) 402-0012 (Fax)
SOUTH DRIVE, MSC 0812
50 Dr South SUITE 50, Bethesda 20892
(301) 594-5283 (Phone)
Certifications:
Internal Medicine, 1970
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1963
Beth Israel Deaconess Medical Center
Clin Ctr-Nih
Harvard Medical School
Graduated: 1963
Beth Israel Deaconess Medical Center
Clin Ctr-Nih
Paul Hunter Plotz, Bethesda MD
Specialties:
Internal Medicine, Rheumatology
Work:
A & R. Branch
9000 Rockville Pike, Bethesda, MD 20892
9000 Rockville Pike, Bethesda, MD 20892
Education:
Harvard University(1963)
Assay Using Recombinant Histidyl-Trna Synthetase
US Patent:
5663066, Sep 2, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/479156
Inventors:
Nina Raben - Rockville MD
Ralph Nichols - Columbia MD
Paul Plotz - Washington DC
Richard Leff - Charleston SC
Ralph Nichols - Columbia MD
Paul Plotz - Washington DC
Richard Leff - Charleston SC
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
National Institutes of Health - Bethesda MD
and Human Services - Washington DC
National Institutes of Health - Bethesda MD
International Classification:
C12N 900, C12N 500, C12P 2106, C07K 100
US Classification:
435183
Abstract:
Recombinant Histidyl tRNA synthetase produced by non-mammalian host cells is used in a sensitive assay to determine the presence of autoimmune diseases in mammals. Methods for isolating, cloning and expressing rHRS are described. In addition, a kit for determining the presence of an autoimmune disease is provided.
Disabling Autophagy As A Treatment For Lysosomal Storage Diseases
US Patent:
2013033, Dec 12, 2013
Filed:
Aug 19, 2013
Appl. No.:
13/970265
Inventors:
- , unknown
Tao Xie - Rockville MD, US
Cynthia Schreiner - Gowanda NY, US
Rebecca Baum - Highland UT, US
Shoichi Takikita - Rockville MD, US
Paul Plotz - Washington DC, US
Tao Xie - Rockville MD, US
Cynthia Schreiner - Gowanda NY, US
Rebecca Baum - Highland UT, US
Shoichi Takikita - Rockville MD, US
Paul Plotz - Washington DC, US
International Classification:
C12N 15/113
US Classification:
514 11, 514 44 A
Abstract:
Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT).
Synthesis And Secretion Of Native Recombinant Lysosomal Enzymes By Liver
US Patent:
2004020, Oct 14, 2004
Filed:
May 14, 2004
Appl. No.:
10/474163
Inventors:
Nina Raben - Rockville MD, US
Nina Lu - Rockville MD, US
Bo Yan - Rockville MD, US
Paul Plotz - Washington DC, US
Yesenia Rivera - Bethesda MD, US
Nina Lu - Rockville MD, US
Bo Yan - Rockville MD, US
Paul Plotz - Washington DC, US
Yesenia Rivera - Bethesda MD, US
International Classification:
C12N009/36, C07H021/04
US Classification:
435/069100, 435/320100, 435/325000, 435/206000, 536/023200
Abstract:
The invention provides recombinant native lysosomal enzymes produced by liver cells, preferably in vitro, and methods of using the native recombinant lysosomal enzymes to treat enzyme deficiencies in vivo. Lysosomal enzymes, including acid alpha-glucosidase (GAA), produced by liver cells apparently undergo the post-translational modifications necessary to achieve good enzymatic activity. The resulting enzymes can be taken up by various other cells and can correct phenotypic abnormalities of distant organs with enzyme deficiencies. In certain preferred embodiments, the enzyme is GAA and the methods are especially adapted for treatment of type II glycogen storage disease in mammals, including humans.
Disabling Autophagy As A Treatment For Lysosomal Storage Diseases
US Patent:
8536148, Sep 17, 2013
Filed:
Sep 2, 2010
Appl. No.:
13/391265
Inventors:
Nina N. Raben - N. Bethesda MD, US
Cynthia Schreiner - Gowanda NY, US
Rebecca Baum - Highland UT, US
Shoichi Takikita - Rockville MD, US
Tao Xie - Rockville MD, US
Paul H. Plotz - Washington DC, US
Cynthia Schreiner - Gowanda NY, US
Rebecca Baum - Highland UT, US
Shoichi Takikita - Rockville MD, US
Tao Xie - Rockville MD, US
Paul H. Plotz - Washington DC, US
Assignee:
The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 2431, 536 241
Abstract:
Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT).
Assay Using Recombinant Histidyl-Trna Synthetase
US Patent:
5484703, Jan 16, 1996
Filed:
Apr 22, 1993
Appl. No.:
8/052404
Inventors:
Nina Raben - Rockville MD
Ralph Nichols - Columbia MD
Paul Plotz - Washington DC
Richard Leff - Charleston SC
Ralph Nichols - Columbia MD
Paul Plotz - Washington DC
Richard Leff - Charleston SC
Assignee:
United States of America - Washington DC
International Classification:
G01N 33564
US Classification:
435 74
Abstract:
Recombinant Histidyl tRNA synthetase produced by non-mammalian host cells is used in a sensitive assay to determine the presence of autoimmune diseases in mammals. Methods for isolating, cloning and expressing rHRS are described. In addition, a kit for determining the presence of an autoimmune disease is provided.